After finishing at $1.89 in the prior trading day, Akebia Therapeutics Inc. (NASDAQ: AKBA) closed at $1.83, down -3.17%. In other words, the price has decreased by -$0.0600 from its previous closing price. On the day, 4317304 shares were traded.
Ratios:
Our goal is to gain a better understanding of AKBA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.03 and its Current Ratio is at 1.18.
On August 28, 2023, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $3.75.
Piper Sandler Upgraded its Neutral to Overweight on May 31, 2023, whereas the target price for the stock was revised from $2 to $4.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 29 ’24 when Butler John P. sold 46,570 shares for $1.58 per share. The transaction valued at 73,581 led to the insider holds 2,044,580 shares of the business.
Dahan Michel sold 8,661 shares of AKBA for $13,684 on Feb 29 ’24. The SVP, Chief Operating Officer now owns 706,932 shares after completing the transaction at $1.58 per share. On Feb 29 ’24, another insider, Burke Steven Keith, who serves as the SVP, Chief Medical Officer of the company, sold 7,169 shares for $1.58 each. As a result, the insider received 11,327 and left with 695,840 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 395.71M and an Enterprise Value of 400.91M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.97. Its current Enterprise Value per Revenue stands at 2.06 whereas that against EBITDA is -99.06.
Stock Price History:
The Beta on a monthly basis for AKBA is 0.77, which has changed by 173.95% over the last 52 weeks, in comparison to a change of 31.54% over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $2.05, while it has fallen to a 52-week low of $0.49. The 50-Day Moving Average of the stock is 1.5490, while the 200-Day Moving Average is calculated to be 1.2516.
Shares Statistics:
The stock has traded on average 2.55M shares per day over the past 3-months and 4.76M shares per day over the last 10 days, according to various share statistics. A total of 194.58M shares are outstanding, with a floating share count of 184.15M. Insiders hold about 12.05% of the company’s shares, while institutions hold 18.43% stake in the company. Shares short for AKBA as of Feb 29, 2024 were 8.11M with a Short Ratio of 3.18, compared to 8.78M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.31% and a Short% of Float of 4.36%.
Earnings Estimates
Its stock is currently analyzed by 3 different market analysts. On average, analysts expect EPS of -$0.09 for the current quarter, with a high estimate of -$0.07 and a low estimate of -$0.11, while EPS last year was -$0.14. The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.02 and low estimates of -$0.08.
Analysts are recommending an EPS of between -$0.21 and -$0.36 for the fiscal current year, implying an average EPS of -$0.27. EPS for the following year is -$0.23, with 3 analysts recommending between $0.17 and -$0.54.
Revenue Estimates
3 analysts predict $40.61M in revenue for the current quarter. It ranges from a high estimate of $42.93M to a low estimate of $38.8M. As of the current estimate, Akebia Therapeutics Inc.’s year-ago sales were $40.13M, an estimated increase of 1.20% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $50.18M, a decrease of -11.00% less than the figure of $1.20% in the same quarter last year. There is a high estimate of $56M for the next quarter, whereas the lowest estimate is $45.79M.
A total of 3 analysts have provided revenue estimates for AKBA’s current fiscal year. The highest revenue estimate was $196.2M, while the lowest revenue estimate was $188.11M, resulting in an average revenue estimate of $193.08M. In the same quarter a year ago, actual revenue was $194.62M, down -0.80% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $185.52M in the next fiscal year. The high estimate is $242.7M and the low estimate is $123.88M. The average revenue growth estimate for next year is down -3.90% from the average revenue estimate for this year.
